Literature DB >> 10731044

Electrophysiological effects of bimoclomol in canine ventricular myocytes.

J Magyar1, T Bányász, P Szigligeti, A Körtvély, A Jednákovits, P P Nánási.   

Abstract

Concentration-dependent effects of bimoclomol, a novel heat shock protein (HSP) coinducer, were studied on the parameters of action potential and transmembrane ionic currents in enzymatically dispersed canine ventricular cardiomyocytes using conventional microelectrode and whole cell voltage clamp techniques. Bimoclomol (10-100 microM) decreased the maximum velocity of depolarization (Vmax) and amplitude of action potentials in a concentration-dependent manner. These effects were fully reversible after a 5-min period of washout in drug-free medium. Action potential duration measured at 50% or 90% level of repolarization (APD-50 and APD-90, respectively) was markedly shortened by bimoclomol. Both APD-50 and APD-90 were decreased, but the reduction in APD-50 was more pronounced. The APD-shortening effect of bimoclomol was significantly reduced in the presence of 20 nM charybdotoxin (inhibitor of the Ca-dependent K current) or 0.5 mM anthracene-9-carboxylic acid (inhibitor of the Ca-dependent Cl current) or 1 microM glibenclamide (inhibitor of the ATP-sensitive K current). In the presence of anthracene-9-carboxylic acid, APD-90 was lengthened by bimoclomol. The APD-shortening effect of bimoclomol was also partially antagonized by chelation of intracellular Ca2+ by application of the cell permeant form of BAPTA, or when using 10 mM EGTA-containing patch pipettes to record action potentials. The Vmax-depressant effect of bimoclomol was not affected by charybdotoxin, anthracene-9-carboxylic acid, glibenclamide, or BAPTA load. In voltage clamped cardiomyocytes bimoclomol (100 microM) had no effect on the amplitude of I(Ca), but decreased significantly the inactivation time constant of I(Ca) (from 19.8+/-1.6 ms to 16.8+/-1.2 ms at 0 mV). Bimoclomol also decreased significantly the amplitude of I(K1) (from -20.5+/-1.1 pA/pF to -16.6+/-0.8 pA/pF at -135 mV), causing reduction in slope of the negative branch of the I-V curve. At positive potentials, however, bimoclomol increased outward current. The bimoclomol-induced current, therefore, was studied in the presence of BaCl2, when I(K1) current was blocked. The bimoclomol-induced current had a reversal potential close to -90 mV. Bimoclomol (100 microM) had no effect on the amplitude or kinetic properties of the transient outward K current (I(to)) and the delayed rectifier K current (I(K)). It is concluded that bimoclomol exerts both Ca-independent (inhibition of I(Na) and I(K1), activation of the ATP-sensitive K current) and Ca-dependent effects (mediated by Ca-activated Cl and probably K currents) in canine ventricular myocytes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731044     DOI: 10.1007/s002109900164

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  9 in total

1.  Effects of thymol on calcium and potassium currents in canine and human ventricular cardiomyocytes.

Authors:  János Magyar; Norbert Szentandrássy; Tamás Bányász; László Fülöp; András Varró; Péter P Nánási
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

2.  Effects of β-adrenoceptor stimulation on delayed rectifier K(+) currents in canine ventricular cardiomyocytes.

Authors:  G Harmati; T Bányász; L Bárándi; N Szentandrássy; B Horváth; G Szabó; J A Szentmiklósi; G Szénási; P P Nánási; J Magyar
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Biphasic effect of bimoclomol on calcium handling in mammalian ventricular myocardium.

Authors:  P P Nánási; S Sárközi; G Szigeti; I Jóna; C Szegedi; A Szabó; T Bányász; J Magyar; P Szigligeti; A Körtvély; L Csernoch; L Kovács; A Jednákovits
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  Effects of SEA0400 and KB-R7943 on Na+/Ca2+ exchange current and L-type Ca2+ current in canine ventricular cardiomyocytes.

Authors:  Péter Birinyi; Károly Acsai; Tamás Bányász; András Tóth; Balázs Horváth; László Virág; Norbert Szentandrássy; János Magyar; András Varró; Ferenc Fülöp; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-08-06       Impact factor: 3.000

5.  Effects of the PKC inhibitors chelerythrine and bisindolylmaleimide I (GF 109203X) on delayed rectifier K+ currents.

Authors:  Gábor Harmati; Ferenc Papp; Norbert Szentandrássy; László Bárándi; Ferenc Ruzsnavszky; Balázs Horváth; Tamás Bányász; János Magyar; György Panyi; Zoltán Krasznai; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-12-01       Impact factor: 3.000

6.  Effects of tacrolimus on action potential configuration and transmembrane ion currents in canine ventricular cells.

Authors:  László Szabó; Norbert Szentandrássy; Kornél Kistamás; Bence Hegyi; Ferenc Ruzsnavszky; Krisztina Váczi; Balázs Horváth; János Magyar; Tamás Bányász; Balázs Pál; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-19       Impact factor: 3.000

7.  Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.

Authors:  János Magyar; Norbert Szentandrássy; Tamás Bányász; Valéria Kecskeméti; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-26       Impact factor: 3.000

8.  L-364,373 fails to activate the slow delayed rectifier K+ current in canine ventricular cardiomyocytes.

Authors:  János Magyar; Balázs Horváth; Tamás Bányász; Norbert Szentandrássy; Péter Birinyi; András Varró; Zsolt Szakonyi; Ferenc Fülöp; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-17       Impact factor: 3.000

9.  Tetrodotoxin blockade on canine cardiac L-type Ca²⁺ channels depends on pH and redox potential.

Authors:  Bence Hegyi; István Komáromi; Kornél Kistamás; Ferenc Ruzsnavszky; Krisztina Váczi; Balázs Horváth; János Magyar; Tamás Bányász; Péter P Nánási; Norbert Szentandrássy
Journal:  Mar Drugs       Date:  2013-06-14       Impact factor: 5.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.